Validation of the archimedes diabetes model

被引:130
作者
Eddy, DM
Schlessinger, L
机构
[1] Kaiser Permanente, Care Management Inst, Oakland, CA 94612 USA
[2] Kaiser Permanente So Calif, Oakland, CA USA
关键词
D O I
10.2337/diacare.26.11.3102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To validate the Archimedes model of diabetes and its complications for a variety of populations, organ systems, treatments, and outcomes. RESEARCH DESIGN AND METHODS - We simulated a variety of randomized controlled trials by repeating in the model the steps taken for the real trials and comparing the results calculated by the model with the results of the trial. Eighteen trials were chosen by an independent advisory committee. Half the trials had been used to help build the model ("internal" or "dependent" validations); the other half had not. Those trials comprise "external" "independent" validations. RESULTS - A total of 74 validation exercises were conducted involving different treatments and outcomes in the 18 trials. For 71 of the 74 exercises there were no statistically significant differences between the results calculated by the model and the results observed in the trial. Considering only the trials that were never used to help build the model-the independent or external validations-the correlation was r = 0.99. Including all of the exercises, the correlation between the outcomes calculated by the model and the outcomes seen in the trials was r = 0.99. When the absolute differences in outcomes between the control and treatment groups were compared, the correlation coefficient was r = 0.97. CONCLUSIONS - The Archimedes diabetes model is a realistic representation of the anatomy, pathophysiology, treatments, and outcomes pertinent to diabetes and its complications for applications that involve the populations, treatments, outcomes, and health care settings spanned by the trials.
引用
收藏
页码:3102 / 3110
页数:9
相关论文
共 28 条
[1]  
[Anonymous], 1991, JAMA, V265, P3255
[2]  
[Anonymous], 1995, Br. Med. J, DOI DOI 10.1136/BMJ.310.6972.83
[3]   The Mt. Hood challenge: cross-testing two diabetes simulation models [J].
Brown, JB ;
Palmer, AJ ;
Bisgaard, P ;
Chan, W ;
Pedula, K ;
Russell, A .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2000, 50 :S57-S64
[4]  
Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
[5]  
*DIAB PREV PROGR R, 2002, NEW ENGL J MED, V356, P393
[6]   Archimedes - A trial-validated model of diabetes [J].
Eddy, DM ;
Schlessinger, L .
DIABETES CARE, 2003, 26 (11) :3093-3101
[7]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[8]   Coronary heart disease risk assessment in diabetes mellitus - a comparison of PROCAM and Framingham risk assessment functions [J].
Game, FL ;
Jones, AF .
DIABETIC MEDICINE, 2001, 18 (05) :355-359
[9]  
Gerstein HC, 2000, LANCET, V355, P253
[10]  
*IRB PAT TYP 2 DIA, 2001, NEW ENGL J MED, V345, P870